A general, virus-free platform to rapidly map SARS-CoV-2 drug resistance

快速绘制 SARS-CoV-2 耐药性图谱的通用无病毒平台

• 批准号: 10436978
• 负责人: Amit Choudhary
• 金额: $ 19.5万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10436978
• 关键词: 2019-nCoV; 5' -exoribonuclease; ACE2; Amino Acids; Antibodies; Antineoplastic Agents; Area; Bar Codes; Binding; Biological Assay; Biology; CASP3 gene; COVID-19; Caspase; Cell Death; Cell Separation; Cells; Clinical; Clustered Regularly Interspaced Short Palindromic Repeats; Code; Collaborations; Development; Dose; Drug Targeting; Drug resistance; Drug usage; Effectiveness; Escape Mutant; Ethics; Evolution; Exploratory/Developmental Grant; Fluorescence; Future; Genotype; Guide RNA; Hot Spot; Laboratories; Mammalian Cell; Maps; Measures; Methods; Mutagenesis; Mutate; Mutation; Nature; Onconase; Pancreatic ribonuclease; Papain; Peptide Hydrolases; Pharmaceutical Preparations; Polymerase; Population; Prevalence; Proteins; RNA; RNA-Directed RNA Polymerase; Reporter; Reporting; Research; Resistance; Resistance development; SARS-CoV-2 inhibitor; SARS-CoV-2 protease; Scheme; Shoulder; System; Technology; Testing; Therapeutic Agents; Universities; Viral; Viral Proteins; Virus; Work; abuse liability; aptamer; base; coronavirus disease; drug candidate; drug development; drug repurposing; inhibitor; interest; medical schools; multidisciplinary; mutant; neutralizing antibody; novel; personalized medicine; pressure; prevent; programs; remdesivir; small molecule; stable cell line; synthetic biology; targeted agent

PROJECT SUMMARY Development or repurposing of drugs for SARS-CoV-2 that causes COVID-19 is an active area of research, but not much effort is being spent on developing platforms to identify mutations that may merge to the inhibitors or neutralizing agents for these targets. Given the widespread prevalence of SARS-CoV-2 and potential abuse of developed therapeutic agents, the emergence of such escape mutants is likely. We will develop a virus-free platform to identify and validate escape mutants for therapeutic agents in the pipeline for SARS-CoV-2.

项目概要 针对导致 COVID-19 的 SARS-CoV-2 的药物的开发或重新利用是一个活跃的研究领域， 但并没有花费太多精力来开发平台来识别可能与抑制剂合并的突变 或这些目标的中和剂。鉴于 SARS-CoV-2 的广泛流行和潜在的滥用 随着治疗药物的开发，这种逃逸突变体的出现是有可能的。我们将开发一种无病毒的 用于识别和验证 SARS-CoV-2 治疗药物的逃逸突变体的平台。

项目成果

Rational Design of Silicon-Based Zinc Ionophores.

硅基锌离子载体的合理设计。

• 发表时间: 2022-06-07
• 作者: Yamada, Kei;Deb, Arghya;Shoba, Veronika M.;Lim, Donghyun;Maji, Basudeb;Modell, Ashley E.;Choudhary, Amit
• 通讯作者: Choudhary, Amit